Clinical Guides
Osteoporosis
An India-contextualised, clinically focused guide to fragility-fracture risk, investigation, prevention and supervised osteoporosis treatment, with explicit limits around drug sequencing, monitoring, pregnancy and local access.
MedNext Academy | 12 min read
Osteoporosis
An India-contextualised, clinically focused guide to fragility-fracture risk, investigation, prevention and supervised osteoporosis treatment, with explicit limits around drug sequencing, monitoring, pregnancy and local access.
Summary
Osteoporosis is skeletal fragility caused by reduced bone strength; it is often silent until a low-trauma vertebral, hip, wrist or other fracture occurs. A fragility fracture is one resulting from a fall from standing height or less, but the mechanism, site and radiology still need interpretation. Diagnosis is not simply a DXA number: prior fracture, age, falls, glucocorticoid exposure, comorbidity and competing mortality change the immediate risk of another fracture. Height loss, new thoracic kyphosis or acute back pain may be the first clue to an unrecognised vertebral fracture.
The clinical task is to identify people at high or very high fracture risk, look for reversible or secondary contributors, prevent falls, ensure adequate nutrition, and choose an evidence-based medicine pathway when benefit exceeds harm. Calcium and vitamin D support bone health and are adjuncts to indicated treatment; they do not replace fracture-risk assessment or an anti-fracture medicine in a person at high risk. Conversely, a prescription should not begin before hypocalcaemia, severe vitamin D deficiency or a probable metabolic bone disorder has been considered.
This is a quarantined educational draft for India. It does not create a universal treatment threshold, a brand-specific regimen, or permission to use a medicine without a current Indian label, renal assessment, dental assessment when indicated, pregnancy check and local specialist plan. It has been reviewed by the MedNext Clinical Team.
How Common Is It?
Osteoporosis becomes more frequent with ageing because bone remodelling, sex-steroid change, sarcopenia, falls and cumulative disease burden interact. The clinically important outcome is fragility fracture, not low bone density alone. Vertebral fractures are commonly missed because they may cause little pain or be discovered incidentally on imaging, while hip fractures usually cause immediate disability and demand urgent multidisciplinary care. A person's near-term risk rises substantially after a recent fragility fracture; this is why post-fracture assessment must not wait for a future screening opportunity.
Indian prevalence figures vary across community surveys, hospital cohorts, DXA reference databases, skeletal sites, menopausal status, urban-rural setting and diagnostic cut-offs. A single national percentage would imply a precision the data do not have. Indian clinicians should therefore avoid using a foreign population prevalence or a marketing-derived bone-age result as a diagnostic label. Local service planning should measure fracture presentations, treatment gaps, DXA access, falls risk and treatment persistence.
Case finding is preferable to indiscriminate testing. Adults with a prior low-trauma fracture, prolonged systemic glucocorticoid exposure, premature menopause or hypogonadism, marked height loss, disorders of absorption, inflammatory disease, chronic kidney or liver disease, endocrine disease, low body weight, recurrent falls or relevant cancer treatment need a structured assessment. Risk tools and DXA inform but do not replace clinical judgement, particularly after a vertebral or hip fracture.
Risk Factors
Major clinical risk factors include increasing age, a previous fragility fracture, parental hip fracture, low body mass, current smoking, excess alcohol, recurrent falls, immobility and long-term oral glucocorticoids. Ask about the actual medicine, dose, duration and future plan rather than recording steroid exposure generically. Rheumatoid arthritis and other inflammatory disorders can increase risk through inflammation, reduced mobility and treatment. Men need assessment too: hypogonadism, alcohol use, glucocorticoids, androgen-deprivation therapy and systemic disease are important contributors.
Secondary causes deserve active search when fracture risk is disproportionate to age or DXA, occurs early, progresses despite apparently appropriate care, or is accompanied by biochemical abnormalities. Histories should cover menopause timing, eating disorder or undernutrition, malabsorption, coeliac symptoms, bariatric surgery, hyperthyroid symptoms, renal stones, chronic kidney disease, liver disease, myeloma features, anticonvulsants, aromatase inhibitors, antiretrovirals and heparin exposure. Vitamin D or calcium deficiency, osteomalacia, hyperparathyroidism and renal bone disease can coexist with low density but require different reasoning.
Falls turn skeletal vulnerability into fracture. Review gait, vision, footwear, neuropathy, postural symptoms, sedative and antihypertensive burden, environmental hazards and fear of falling. A low bone-density result without falls assessment is incomplete care. Equally, a high falls burden should not be used to dismiss osteoporosis treatment: the plan should reduce both fracture susceptibility and the chance of impact.
Diagnosis
History
Ask about every fracture after adult age, its mechanism, radiology, treatment and recovery; specifically ask about height loss, sudden back pain, stooped posture and prior vertebral imaging. Establish menopausal or gonadal history, glucocorticoid exposure, smoking, alcohol, diet, calcium-containing foods, vitamin D products and falls. Clarify family hip fracture, kidney stones, malabsorption, renal or liver disease, inflammatory disease, endocrine symptoms, cancer therapy and medicines. Severe focal bone pain, fever, weight loss, anaemia, neurological symptoms or night pain suggests an alternative diagnosis or complication.
Examination
Measure current height and compare with documented previous height where possible. Observe gait, sit-to-stand transfer, balance, kyphosis and focal spinal tenderness without provocative manoeuvres. Examine for frailty, muscle weakness, visual impairment, neurological deficit, thyroid disease, cushingoid features, inflammatory arthritis, malnutrition and signs of chronic liver or renal disease. A normal examination does not exclude osteoporosis; focal tenderness, a new deformity or inability to weight-bear needs fracture assessment rather than reassurance.
Investigations
DXA is used with clinical risk to quantify density and follow selected patients, but it is not the sole gatekeeper after a major fragility fracture. Investigations should be targeted: full blood count, renal function, calcium, phosphate, alkaline phosphatase, liver tests, thyroid testing, vitamin D, parathyroid hormone, coeliac testing, serum protein studies or sex-hormone assessment are chosen from the phenotype. Check for vertebral fracture on appropriate spine or other imaging. Do not mistake a low DXA result caused by osteomalacia or renal bone disease for a simple antiresorptive indication.
Differential Diagnosis
Osteoporosis is a reduction in bone strength, whereas osteomalacia is defective mineralisation; both can produce low-trauma fractures and low DXA values. Bone pain, proximal weakness, low phosphate, abnormal alkaline phosphatase or marked vitamin D deficiency should prompt assessment for a mineralisation disorder before treatment is selected. Chronic kidney disease-mineral and bone disorder has altered turnover and mineral metabolism that cannot be safely reduced to routine postmenopausal osteoporosis.
Primary hyperparathyroidism, hyperthyroidism, Cushing syndrome, hypogonadism, myeloma, metastatic cancer, inflammatory disease, malabsorption and medicines may either cause secondary osteoporosis or explain symptoms through another mechanism. Focal persistent pain, constitutional symptoms, anaemia, hypercalcaemia, destructive radiology or an unexplained monoclonal protein requires a malignancy pathway. Paget disease has characteristic focal remodelling and imaging findings; osteoarthritis may elevate DXA values at the spine and should not be interpreted as protection from fracture.
Distinguish a traumatic fracture from a fragility fracture by the energy involved, but do not make a simplistic binary judgement in an older adult with a fall. Stress injury, insufficiency fracture and atypical femoral fracture have different contexts and imaging patterns. New thigh or groin pain in a person receiving long-term antiresorptive treatment needs prompt imaging and specialist advice rather than a routine refill. Clinical reasoning must reconcile symptoms, imaging, biochemical tests, medicines and falls risk.
Management
Start with fracture prevention that is useful whatever medicine is eventually chosen: smoking cessation, moderation of alcohol, adequate protein and calcium-containing foods, correction of established vitamin D inadequacy where indicated, weight-bearing and muscle-strengthening activity tailored to fracture, balance training and falls prevention. Exercise advice after vertebral fracture, severe frailty or recent surgery should be supervised and should not promise that exercise alone restores bone strength. Coordinate acute fracture care, analgesia, rehabilitation and future-risk assessment; a fracture liaison model can close the common treatment gap.
For high fracture risk, bisphosphonates are a common initial antiresorptive option in international guidance, with route chosen according to tolerance, adherence, absorption, renal function and local availability. Denosumab is an alternative in selected patients but requires a credible long-term plan; its effect reverses after delayed or stopped treatment, so it is not a drug-holiday medicine. Very high risk, especially severe or multiple vertebral fractures, merits specialist consideration of an anabolic or bone-forming strategy where licensed and accessible. Follow a completed anabolic course with antiresorptive treatment to retain gain; do not improvise sequences.
Choice is individual. Verify fracture risk, treatment objective, prior exposure, calcium and vitamin D status, renal function, dental and jaw history when relevant, cardiovascular history for romosozumab consideration, adherence capacity, affordability and follow-up. A medicine that cannot be obtained on schedule is unsafe if stopping creates rebound risk. Record the planned review date and the contingency for illness, surgery, relocation or pregnancy.
Prescribing Information
Do not prescribe from a DXA report alone. Before an antiresorptive or anabolic medicine, document fracture phenotype, baseline calcium, relevant renal function, vitamin D status where clinically indicated, prior therapy and contraindications in the current Indian product information. Correct untreated hypocalcaemia and investigate its cause. Oral bisphosphonates require the ability to follow administration instructions and tolerate upper gastrointestinal exposure; IV therapy and denosumab have different renal, calcium and service-delivery considerations. The exact product, formulation, frequency and dose must come from the locally licensed label or specialist protocol, not from this guide.
Plan monitoring around the medicine and patient. Reassess adherence, adverse effects, incident fractures, falls and new secondary causes. Use DXA and, where locally available and appropriate, bone turnover markers as adjuncts rather than sole measures of response. Antiresorptives carry rare risks of osteonecrosis of the jaw and atypical femoral fracture; absolute risk, cancer-dose distinctions and individual risk factors should be discussed without withholding beneficial therapy through fear alone. New exposed jaw bone, non-healing oral lesion, invasive dental procedure planning or thigh/groin pain warrants clinical review.
Duration is risk-based. NOGG advises reassessment after at least five years of oral or three years of intravenous bisphosphonate treatment, with longer therapy for ongoing high-risk features; lower-risk pauses require a review plan. Denosumab must not be stopped or delayed without planned subsequent therapy when renal function permits. Pregnancy should be discussed before starting: osteoporosis medicines are not routine pregnancy treatment, and women who may conceive need specialist advice on timing, contraception and drug-specific persistence.
When to Refer
Refer promptly after a hip or clinical vertebral fragility fracture, multiple fractures, a fracture while taking apparently adherent therapy, or a fracture in a younger adult or premenopausal woman. Metabolic bone, endocrinology, rheumatology, geriatric, nephrology, oncology or orthopaedic input depends on the suspected cause and current problem. A specialist opinion is appropriate before anabolic therapy, denosumab where continuity is uncertain, complex drug sequencing, advanced chronic kidney disease, hypercalcaemia or hypocalcaemia, suspected osteomalacia, high-dose glucocorticoid exposure or uncommon secondary causes.
Dental referral is not automatic before all antiresorptive treatment. Arrange dental assessment when there is active oral disease, a non-healing lesion, planned invasive dental work or high jaw-risk context, and coordinate rather than casually interrupt therapy. Oral and maxillofacial assessment is urgent for exposed bone, fistula, persistent jaw pain or infection. Nephrology should guide chronic kidney disease with mineral abnormalities; standard eGFR-based shortcuts may be unsafe.
Refer for falls, physiotherapy, occupational therapy, vision and social support where these alter risk or independent living. In constrained settings, a clear referral question and a documented interim safety plan are better than unstructured supplementation. Send fracture imaging, DXA report with skeletal sites, serial height, laboratory results, medicine exposure, dental concerns and pregnancy intention. The recipient should be able to see why the referral is about fracture prevention, diagnostic uncertainty or medication safety.
Red Flags
Urgently assess new inability to bear weight, suspected hip fracture, acute severe spinal pain with neurological deficit, bowel or bladder disturbance, fever or trauma. Back pain with progressive weakness, saddle symptoms, cancer history or systemic illness is not presumed to be an uncomplicated vertebral fracture. Severe hypercalcaemia symptoms, symptomatic hypocalcaemia, rapidly falling renal function or delirium need acute assessment before long-term bone treatment is debated.
Think beyond routine osteoporosis with recurrent fractures at a young age, unexplained anaemia, weight loss, night pain, bone swelling, marked hypercalcaemia, persistent hypophosphataemia, high alkaline phosphatase of uncertain origin, renal stones or an abnormal protein study. These may indicate malignancy, hyperparathyroidism, osteomalacia, renal tubular disease or another metabolic disorder. A severe fracture after minimal trauma needs secondary prevention, but the investigative path should remain open.
Treatment red flags include an injected dose missed or delayed without a continuation plan, new thigh or groin pain during long-term antiresorptive exposure, exposed jaw bone or non-healing socket, painful dental infection, rash or breathlessness after treatment, and a new fragility fracture despite verified adherence. Do not tell a patient to stop denosumab independently; urgent contact with the prescriber is safer. Pregnancy discovered during therapy, planned conception, or breast-feeding also requires prompt specialist medication review.
Indian Clinical Context
India has heterogeneous access to DXA, vertebral imaging, fracture liaison services, laboratory quality assurance, dental care, rehabilitation, endocrinology and expensive injectable medicines. A safe plan starts with what can actually be measured, obtained and followed. A generic oral medicine with reliable supply, counselling and review may be safer than an intermittently available injection, but selection still requires individual fracture risk and current Indian prescribing information. Do not imply that a UK or US threshold is an Indian statutory rule.
Nutrition counselling should be practical: discuss regional calcium-containing foods, protein, vegetarian or vegan patterns, affordability, fasting, lactose intolerance and duplicate supplements. Sun exposure advice cannot be used as a precise vitamin D dose and must take heat, skin protection, occupation and cultural context into account. Calcium and vitamin D products vary widely in strength and formulation. Verify all prescribed, over-the-counter, traditional and combination products to avoid inadvertent excess or the false belief that supplements alone treat a high-risk fracture state.
Care should not blame patients for falls or nutrition shaped by poverty, disability, unsafe housing or caregiving. Community health workers, primary-care teams, pharmacists, physiotherapists, dental teams and families can support adherence and fall prevention with consent. Where advanced imaging or specialist medicines are unavailable, prioritise fracture identification, correction of remediable deficits, fall-risk reduction and referral. This educational draft does not override state procurement rules, hospital protocols, local resistance-free formulary decisions or human clinical review.
NMC Competency Mapping
The NMC CBME Curriculum 2024 includes osteoporosis within the orthopaedics teaching of metabolic bone disorders. Learners should be able to describe aetiopathogenesis, clinical features, investigations and principles of management, and then recognise the limits of undergraduate responsibility. This guide connects that outcome to the clinical sequence of identifying fragility fracture, estimating risk, investigating secondary causes, counselling on falls and nutrition, and escalating medication decisions that need supervision.
For assessment, students should distinguish osteoporosis from osteomalacia and renal bone disease, identify a fragility fracture from history and imaging, explain why a recent fracture changes future risk, and interpret a DXA result in context. They should obtain a medicine history that identifies glucocorticoids and treatment-adherence barriers; they should not independently initiate complex anabolic, denosumab-discontinuation or pregnancy plans.
Communication competence includes explaining that a fracture is not an inevitable part of ageing, discussing uncertainty honestly, using teach-back for administration and follow-up, and avoiding stigma around falls, body size, menopause or diet. Teamwork includes referral to orthopaedics for acute fracture, metabolic-bone expertise for secondary causes, physiotherapy for safe rehabilitation and primary care for continuity. Curriculum mapping is educational only; it does not confer a licence to prescribe or certify this quarantined guide as reviewed.
Key Exam Pearls for NEET PG
A fragility fracture can establish clinical osteoporosis even when a DXA scan is unavailable; DXA quantifies density but must be interpreted with clinical risk. Ask actively about painless vertebral fractures: height loss, kyphosis and incidental vertebral compression on chest or abdominal imaging matter. In an older adult, a recent low-trauma fracture is an urgent secondary-prevention signal, not merely an orthopaedic event.
Separate osteoporosis from osteomalacia. Osteoporosis is loss of bone strength; osteomalacia is impaired mineralisation and more often brings bone pain, proximal weakness and mineral-biochemistry abnormalities. Low DXA does not distinguish them. Before potent antiresorptive therapy, resolve unexplained hypocalcaemia or biochemical evidence of a mineralisation disorder.
Sequence is a frequent examination and clinical-safety point. Very-high-risk patients may require specialist consideration of bone-forming therapy, followed by antiresorptive therapy to preserve gain. Bisphosphonate duration is reviewed by residual fracture risk, not stopped automatically. Denosumab has no routine holiday: delayed or stopped treatment requires a subsequent antiresorptive plan. Remember rare harms without overcalling them: new thigh pain suggests atypical femoral fracture evaluation; jaw symptoms need assessment; renal function, calcium status and pregnancy intention alter management.
Frequently Asked Questions
Can calcium and vitamin D alone treat established high fracture risk?
No. Adequate calcium and vitamin D support bone health and are often adjuncts to indicated therapy, but they do not replace fracture-risk assessment or an anti-fracture medicine for a person at high risk. Check dietary intake, supplements and relevant biochemical abnormalities without assuming everyone needs the same product or dose.
Why is denosumab discontinuation considered a clinical safety issue?
Its antiresorptive effect reverses after delayed or stopped dosing. International guidance advises that it should not be stopped without a planned subsequent antiresorptive therapy when appropriate. The plan must be arranged with the prescriber, renal and calcium status, local access and individual fracture risk in view.
Does a normal DXA result rule out a fragility fracture problem?
No. Fracture risk reflects age, prior fracture, falls, glucocorticoids, comorbidity and bone density. A vertebral or hip fragility fracture can demand secondary prevention even if a DXA result is unavailable or does not appear striking. Imaging, history and secondary-cause assessment remain important.
What should someone do if they develop thigh pain during treatment?
Report persistent new thigh or groin pain promptly. Long-term antiresorptive exposure is associated with a rare atypical femoral fracture risk, and evaluation may include imaging of the symptomatic and sometimes opposite femur. Do not make abrupt medication changes without the treating team because the safer response depends on the medicine and fracture risk.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic